SCRIP "Anima brings small molecule discovery to mRNA space"
May 30th, 2019
Yochi Slonim, co-founder and CEO of Anima Biotech, explains how the company occupies a unique space in mRNA-based drug development. While other companies are working with messenger RNA technologies, Anima Biotech says it is the only one discovering small molecule drugs to decrease or increase the production of target proteins regulating the translation of mRNA. Slonim spoke to Mike Ward about the technological concept and its early-stage pipeline.